Acylcarnitines in Cancer Metabolism: Mechanistic Insights and Stratification Potential

Area of Science:

• Metabolic reprogramming in oncology
• Mitochondrial fatty acid oxidation (FAO)
• Acylcarnitine (AC) metabolism and signaling

Background:

• Cancer cells reprogram metabolism for survival and proliferation.
• Fatty acid oxidation (FAO) is a critical driver of oncogenesis and therapeutic resistance.
• Acylcarnitines (ACs) are essential for mitochondrial fatty acid transport and act as signaling molecules.

Purpose of the Study:

• To review the acylcarnitine (AC) metabolic axis in cancer.
• To explore the role of ACs in mitochondrial oxidative throughput and cellular homeostasis.
• To evaluate ACs as biomarkers and therapeutic targets in oncology.

Main Methods:

• Review of the biochemical machinery governing cellular AC homeostasis, including CPT, CACT, and OCTN2.
• Evaluation of altered AC profiles as non-invasive biomarkers for cancer diagnosis and risk stratification.
• Scrutiny of therapeutic strategies targeting the AC-FAO axis for cancer treatment.

Main Results:

• ACs are crucial intermediates in mitochondrial fatty acid transport and signaling.
• Altered AC profiles can serve as biomarkers for early diagnosis and risk stratification in malignancies.
• Targeting the AC-FAO axis can sensitize tumors to chemotherapy and immunotherapy.

Conclusions:

• The AC metabolic axis is a pivotal player in cancer progression and therapeutic resistance.
• AC profiles hold significant potential as non-invasive biomarkers in oncology.
• Targeting AC metabolism represents a promising avenue for precision metabolic oncology and personalized therapies.